The ENCePP Code of Conduct: A best practise for scientific independence and transparency in noninterventional postauthorisation studies-Reference-Cited by-同舟云学术

The ENCePP Code of Conduct: A best practise for scientific independence and transparency in noninterventional postauthorisation studies

Published:2019-03-05 Issue:4 Volume:28 Page:422-433
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Gini Rosa¹^ORCID,Fournie Xavier²,Dolk Helen³^ORCID,Kurz Xavier⁴^ORCID,Verpillat Patrice⁵,Simondon François⁶,Strassmann Valerie⁷,Apostolidis Kathi⁸^ORCID,Goedecke Thomas⁴^ORCID

Affiliation:

1. Osservatorio di EpidemiologiaAgenzia regionale di sanità della Toscana Florence Italy

2. Global Medical AffairsICON Commercialisation & Outcomes Lyon France

3. Faculty of Life and Health SciencesUniversity of Ulster at Jordanstown Jordanstown UK

4. Pharmacovigilance and Epidemiology Department, Inspections, Human Medicines Pharmacovigilance and Committees DivisionEuropean Medicines Agency Amsterdam The Netherlands

5. Global EpidemiologyMerck Group Darmstadt Germany

6. Mother and Child Health Research Unit IRDUniversite Paris Descartes Paris France

7. PharmacovigilanzBundesinstitut für Arzneimittel und Medizinprodukte (BfArM) Bonn Germany

8. Vice PresidentEuropean Cancer Patient Coalition (ECPC) Brussels Belgium

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.4763

Reference25 articles.

1. Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)

2. Scope and Impact of Financial Conflicts of Interest in Biomedical Research

3. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).Guide on Methodological Standards in Pharmacoepidemiology (Revision 7) (EMA/95098/2010) [Internet]. [cited2018Oct 15]. Available from:http://www.encepp.eu/standards_and_guidances/documents/ENCePPGuideonMethStandardsinPE_Rev7.pdf

4. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).ENCePP Checklist for Study Protocols (Revision 3) (EMA/540136/2009) [Internet]. 2016 [cited2018Oct 15]. Available from:http://www.encepp.eu/standards_and_guidances/checkListProtocols.shtml

5. Impact of study outcome on submission and acceptance metrics for peer reviewed medical journals: six year retrospective review of all completed GlaxoSmithKline human drug research studies

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transparency in the secondary use of health data: Assessing the status quo of guidance and best practices;2024-08-11

2. Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping review;Pharmacoepidemiology and Drug Safety;2024-05

3. HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-world Evidence Studies on Treatment Effects (Japanese Version)： A Good Practices Report of a Joint ISPE/ISPOR Task Force;Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku;2023-06-30

4. Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study;Drug Safety;2023-06-09

5. HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real‐world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force;Pharmacoepidemiology and Drug Safety;2022-10-10